ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.The European respiratory journal · 2023Pooled it
- Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design.Respiratory research · 2022Trial
- Cardiac magnetic resonance parameters for prognostic stratification in pulmonary hypertension: A longitudinal study.Journal of the Chinese Medical Association : JCMA · 2025Article
- Value of the 6 min walk test in detecting cardiopulmonary involvement in patients with systemic sclerosis.RMD open · 2025Article
- Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study.BMC pulmonary medicine · 2024Article
- A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension.Pulmonary circulation · 2024Review
- IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.Pulmonary circulation · 2024Article
- Stress hyperglycemia is associated with poor outcome in critically ill patients with pulmonary hypertension.Frontiers in endocrinology · 2024Article
- Comparison of cardiac magnetic resonance imaging, functional and haemodynamic variables in pulmonary arterial hypertension: insights from REPAIR.ERJ open research · 2024Article
- Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives.Journal of clinical medicine · 2023Review
- Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes.Circulation research · 2023Article
- When more is more: the role of additional upfront therapy in pulmonary arterial hypertension.ERJ open research · 2023Article
- [Within-subject variability of the 6-minute walk test].Revista medica del Instituto Mexicano del Seguro Social · 2022Observational
- Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.Journal of cachexia, sarcopenia and muscle · 2021Article
- Daily Step Counts Are Associated with Hospitalization Risk in Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2021Article
- Low-Dose Dobutamine Stress Echocardiography for the Early Detection of Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis Whose Resting Echocardiography Is Non-Diagnostic for Pulmonary Hypertension.Journal of clinical medicine · 2021Article
- Cardiovascular complications in patients with interstitial lung disease and their correlation with 6-minute walk test and spirometry: A single-center study.Journal of family medicine and primary care · 2021Article
- Multiple Manifestations of Systemic Sclerosis Affect Walk Distance.American journal of respiratory and critical care medicine · 2021Article
- The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2021Article
- Shuttling toward Improved Clinic-based Assessment of Exercise Capacity in Pulmonary Arterial Hypertension.Annals of the American Thoracic Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of change in exercise capacity using the 6-min walk distance (6MWD) test has been the primary end-point in the majority of pulmonary arterial hypertension (PAH) clinical trials. The 6MWD has some advantages as an end-point in such studies. It is simple and inexpensive to perform, reproducible and validated. In short-term studies with small patient numbers, as is typical in a rare disease like PAH, using change from baseline in 6MWD as the primary outcome measure demonstrated statistically significant differences between placebo and study drugs, leading to their approval. However, there have been increasing calls for clinical trials to employ primary end-points that reflect long-term disease progression and morbidity. While the 6MWD was initially considered to be a potentially reliable surrogate for disease progression in PAH, there is increasing evidence that this is not necessarily the case. Given this, there is a need to re-examine the role of 6MWD in PAH trials, and to evaluate the evidence supporting whether there is a need to move from 6MWD to more robust measures of clinical outcomes, such as morbidity and mortality. However, in the clinic the 6MWD test, alongside symptoms, haemodynamics and biomarkers, remains a useful tool in the assessment and management of PAH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.